TY - JOUR
T1 - Speech and Language Therapy for Acquired Central Dysgraphia in Neurological Patients
T2 - A Systematic Review to Describe and Identify Trainings for Clinical Practice
AU - Biddau, Federica
AU - Brisotto, Camilla
AU - Innocenti, Tiziano
AU - Ranaldi, Sara
AU - Meneghello, Francesca
AU - D’imperio, Daniela
AU - Nordio, Sara
N1 - Publisher Copyright:
© 2023 American Speech-Language-Hearing Association.
PY - 2023/3/9
Y1 - 2023/3/9
N2 - PURPOSE: Acquired central dysgraphia is a heterogeneous neurological disorder that usually co-occurs with other language disorders. Written language training is relevant to improve everyday skills and as a compensatory strategy to support limited oral communication. A systematic evaluation of existing writing treatments is thus needed.METHOD: We performed a systematic review of speech and language therapies for acquired dysgraphia in studies of neurological diseases (PROSPERO: CRD42018084221), following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) checklist with a search on several databases for articles written in English and published until August 31, 2021. Only methodological well-designed studies were included. Further assessment of methodological quality was conducted by means of a modified version of the Downs and Black checklist.RESULTS: Eleven studies of 43 patients in total were included. For each study, we collected data on type of population, type of impairment, experimental design, type of treatment, and measured outcomes. The studies had a medium level of assessed methodological quality. An informative description of treatments and linkages to deficits is reported.CONCLUSIONS: Although there is a need for further experimental evidence, most treatments showed good applicability and improvement of written skills in patients with dysgraphia. Lexical treatments appear to be more frequently adopted and more flexible in improving dysgraphia and communication, especially when a multimodal approach is used. Finally, the reported description of treatment modalities for dysgraphia in relation to patients' deficits may be important for providing tailored therapies in clinical management.
AB - PURPOSE: Acquired central dysgraphia is a heterogeneous neurological disorder that usually co-occurs with other language disorders. Written language training is relevant to improve everyday skills and as a compensatory strategy to support limited oral communication. A systematic evaluation of existing writing treatments is thus needed.METHOD: We performed a systematic review of speech and language therapies for acquired dysgraphia in studies of neurological diseases (PROSPERO: CRD42018084221), following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) checklist with a search on several databases for articles written in English and published until August 31, 2021. Only methodological well-designed studies were included. Further assessment of methodological quality was conducted by means of a modified version of the Downs and Black checklist.RESULTS: Eleven studies of 43 patients in total were included. For each study, we collected data on type of population, type of impairment, experimental design, type of treatment, and measured outcomes. The studies had a medium level of assessed methodological quality. An informative description of treatments and linkages to deficits is reported.CONCLUSIONS: Although there is a need for further experimental evidence, most treatments showed good applicability and improvement of written skills in patients with dysgraphia. Lexical treatments appear to be more frequently adopted and more flexible in improving dysgraphia and communication, especially when a multimodal approach is used. Finally, the reported description of treatment modalities for dysgraphia in relation to patients' deficits may be important for providing tailored therapies in clinical management.
UR - http://www.scopus.com/inward/record.url?scp=85150001044&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85150001044&partnerID=8YFLogxK
U2 - 10.1044/2022_AJSLP-22-00042
DO - 10.1044/2022_AJSLP-22-00042
M3 - Review article
C2 - 36857041
SN - 1058-0360
VL - 32
SP - 762
EP - 785
JO - American journal of speech-language pathology
JF - American journal of speech-language pathology
IS - 2
ER -